OTCM
RNLXY
Market cap32mUSD
Jun 10, Last price
0.21USD
1D
1.43%
1Q
4.36%
IPO
33.13%
Name
Renalytix PLC
Chart & Performance
P/E
—
P/S
30.82
EPS
—
Div Yield, %
—
Shrs. gr., 5y
23.71%
Rev. gr., 5y
-86.05%
Revenues
2m
-32.74%
Net income
-33m
L-26.64%
CFO
-30m
L-7.84%
Earnings
Sep 29, 2025
Profile
Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record systems to generate a unique patient risk score. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. Renalytix AI plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers; and Kantaro Biosciences LLC for developing and commercializing laboratory tests for the detection of antibodies against SARS-CoV-2. The company also has a partnership agreement with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to implement an advanced clinical care model designed to improve kidney health and reduce kidney disease progression and kidney failure in high-risk populations. The company was formerly known as Renalytix AI plc and changed its name to Renalytix Plc in June 2021. Renalytix Plc was incorporated in 2018 and is headquartered in New York, New York.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|
| 2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | |
| Income | |||||||
Revenues | 2,289 -32.74% | 3,403 14.58% | 2,970 99.20% | ||||
Cost of revenue | 31,174 | 60,056 | 29,651 | ||||
Unusual Expense (Income) | |||||||
NOPBT | (28,885) | (56,653) | (26,681) | ||||
NOPBT Margin | |||||||
Operating Taxes | 4 | 2 | 7,104 | ||||
Tax Rate | |||||||
NOPAT | (28,889) | (56,655) | (33,785) | ||||
Net income | (33,456) -26.64% | (45,607) -19.61% | (56,732) 82.95% | ||||
Dividends | |||||||
Dividend yield | |||||||
Proceeds from repurchase of equity | 13,626 | 20,557 | 9,213 | ||||
BB yield | -114.51% | -22.23% | -11.88% | ||||
| Debt | |||||||
Debt current | 4,204 | 4,593 | 4,823 | ||||
Long-term debt | 4,376 | 7,728 | 8,249 | ||||
Deferred revenue | |||||||
Other long-term liabilities | |||||||
Net debt | 3,900 | (15,281) | (28,270) | ||||
| Cash flow | |||||||
Cash from operating activities | (30,111) | (32,674) | (45,745) | ||||
CAPEX | (4) | (694) | |||||
Cash from investing activities | (4) | (694) | |||||
Cash from financing activities | 10,250 | 15,118 | 25,515 | ||||
FCF | (26,711) | (54,785) | (34,417) | ||||
| Balance | |||||||
Cash | 4,680 | 26,142 | 44,077 | ||||
Long term investments | 1,460 | (2,735) | |||||
Excess cash | 4,566 | 27,432 | 41,194 | ||||
Stockholders' equity | (212,747) | (100,335) | (52,720) | ||||
Invested Capital | 213,428 | 130,919 | 108,457 | ||||
ROIC | |||||||
ROCE | |||||||
| EV | |||||||
Common stock shares outstanding | 108,179 | 82,210 | 73,837 | ||||
Price | 0.11 -90.22% | 1.13 7.14% | 1.05 -90.28% | ||||
Market cap | 11,900 -87.13% | 92,486 19.29% | 77,529 -89.96% | ||||
EV | 15,800 | 77,205 | 49,259 | ||||
EBITDA | (28,521) | (54,161) | (24,068) | ||||
EV/EBITDA | |||||||
Interest | 2 | ||||||
Interest/NOPBT | |||||||